A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence

Science Translational Medicine

Volumn 4, Issue 146, 2012, Pages

  Wee, Sunmee ^a   Vendruscolo, Leandro F ^a   Misra, Kaushik K ^a   Schlosburg, Joel E ^a   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BUPRENORPHINE; COCAINE; DELTA OPIATE RECEPTOR; DEPADE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COCAINE DEPENDENCE; COMPULSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

ANIMALS; BUPRENORPHINE; COCAINE; COCAINE-RELATED DISORDERS; MALE; NALOXONE; NALTREXONE; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84864876719     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003948     Document Type: Article

References (65)

1. J. Kakko, L. Grönbladh, K. D. Svanborg, J. von Wachenfeldt, C. Rück, B. Rawlings, L. H. Nilsson, M. Heilig, A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. Am. J. Psychiatry 164, 797-803 (2007).
2. M. Heilig, M. Egli, Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms. Pharmacol. Ther. 111, 855-876 (2006).
3. M. V. Burke, J. O. Ebbert, J. T. Hays, Treatment of tobacco dependence. Mayo Clin. Proc. 83, 479-483 (2008).
4. H. D. Kleber, Pharmacologic treatments for heroin and cocaine dependence. Am. J. Addict. 12 (Suppl. 2), S5-S18 (2003).
5. T. R. Kosten, Current pharmacotherapies for opioid dependence. Psychopharmacol. Bull. 26, 69- 74 (1990).
6. N. K. Mello, J. H. Mendelson, Buprenorphine suppresses heroin use by heroin addicts. Science 207, 657-659 (1980).
7. N. K. Mello, S. E. Lukas, J. B. Kamien, J. H. Mendelson, J. Drieze, E. J. Cone, The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 260, 1185-1193 (1992).
8. R. E. Sorge, J. Stewart, The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration. Psychopharmacology 188, 28-41 (2006).
9. M. E. Carroll, S. T. Lac, Effects of buprenorphine on self-administration of cocaine and a nondrug reinforcer in rats. Psychopharmacology 106, 439-446 (1992).
10. R. E. Sorge, H. Rajabi, J. Stewart, Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement. Neuropsychopharmacology 30, 1681-1692 (2005).
11. S. D. Comer, S. T. Lac, L. K. Curtis, M. E. Carroll, Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced responding in rats. J. Pharmacol. Exp. Ther. 267, 1470-1477 (1993).
12. R. S. Schottenfeld, J. R. Pakes, A. Oliveto, D. Ziedonis, T. R. Kosten, Buprenorphine vsmethadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch. Gen. Psychiatry 54, 713-720 (1997).
13. R. W. Foltin, M. W. Fischman, Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J. Pharmacol. Exp. Ther. 278, 1153-1164 (1996).
14. I. D.Montoya, D. A. Gorelick, K. L. Preston, J. R. Schroeder, A. Umbricht, L. J. Cheskin, W. R. Lange, C. Contoreggi, R. E. Johnson, P. J. Fudala, Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin. Pharmacol. Ther. 75, 34-48 (2004).
15. J. E. Dum, A. Herz, In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br. J. Pharmacol. 74, 627-633 (1981).
16. D. V. Romero, J. S. Partilla, Q. X. Zheng, S. O. Heyliger, Q. Ni, K. C. Rice, J. Lai, R. B. Rothman, Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective μ/κ antagonist in the [35S]-GTP-γ-S functional binding assay. Synapse 34, 83-94 (1999).
17. A. E. Takemori, B. Y. Ho, J. S. Naeseth, P. S. Portoghese, Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246, 255-258 (1988).
18. M. L. Kraus, D. P. Alford, M. M. Kotz, P. Levounis, T. W. Mandell, M. Meyer, E. A. Salsitz, N. Wetterau, S. A. Wyatt, Statement of the American Society of Addiction Medicine consensus panel on the use of buprenorphine in office-based treatment of opioid addiction. J. Addict. Med. 5, 254-263 (2011).
19. S. D. Comer, M. A. Sullivan, S. K. Vosburg, J. Manubay, L. Amass, Z. D. Cooper, P. Saccone, H.D. Kleber, Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphinemaintained intravenous heroin users. Addiction 105, 709-718 (2010).
20. P. S. Frankel, M. E. Alburges, L. Bush, G. R. Hanson, S. J. Kish, Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 55, 41-46 (2008).
21. Y. L. Hurd, M. Herkenham, Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13, 357-369 (1993).
22. J. B. Daunais, D. C. Roberts, J. F. McGinty, Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport 4, 543-546 (1993).
23. E. M. Unterwald, J. M. Rubenfeld, M. J. Kreek, Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 5, 1613-1616 (1994).
24. P. L. Smiley, M. Johnson, L. Bush, J. W. Gibb, G. R. Hanson, Effects of cocaine on extrapyramidal and limbic dynorphin systems. J. Pharmacol. Exp. Ther. 253, 938 -943 (1990).
25. S. Wee, L. Orio, S. Ghirmai, J. R. Cashman, G. F. Koob, Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology 205, 565-575 (2009).
26. V. A. Redila, C. Chavkin, Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology 200, 59-70 (2008).
27. G. F. Koob, A role for brain stress systems in addiction. Neuron 59, 11- 34 (2008).
28. G. F. Koob, M. LeMoal,Drug abuse:Hedonic homeostatic dysregulation. Science 278, 52-58 (1997).
29. N. E. Goeders, Potential involvement of anxiety in the neurobiology of cocaine. Ann. N. Y. Acad. Sci. 654, 357-367 (1992).
30. N. E. Goeders, Stress and cocaine addiction. J. Pharmacol. Exp. Ther. 301, 785-789 (2002).
31. S. D. Mague, A. M. Pliakas, M. S. Todtenkopf, H. C. Tomasiewicz, Y. Zhang, W. C. Stevens Jr., R. M. Jones, P. S. Portoghese, W. A. Carlezon Jr., Antidepressant-like effects of k-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 305, 323-330 (2003).
32. A. Pfeiffer, V. Brantl, A. Herz, H. M. Emrich, Psychotomimesis mediated by kappa opiate receptors. Science 233, 774-776 (1986).
33. H. C. Tomasiewicz, M. S. Todtenkopf, E. H. Chartoff, B. M. Cohen, W. A. Carlezon Jr., The κ-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol. Psychiatry 64, 982-988 (2008).
34. J. D. Jentsch, J. R. Taylor, Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behavior by reward-related stimuli. Psychopharmacology 146, 373-390 (1999).
35. L. J. Vanderschuren, B. J. Everitt, Drug seeking becomes compulsive after prolonged cocaine self-administration. Science 305, 1017-1019 (2004).
36. W. A. Carlezon Jr., J. Thome, V. G. Olson, S. B. Lane-Ladd, E. S. Brodkin, N. Hiroi, R. S. Duman, R. L. Neve, E. J. Nestler, Regulation of cocaine reward by CREB. Science 282, 2272-2275 (1998).
37. S. Wee, C. D. Mandyam, D. M. Lekic, G. F. Koob, α1-Noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. Eur. Neuropsychopharmacol. 18, 303-311 (2008).
38. S. H. Ahmed, G. F. Koob, Transition from moderate to excessive drug intake: Change in hedonic set point. Science 282, 298-300 (1998).
39. G. Gerra, A. Fantoma, A. Zaimovic, Naltrexone and buprenorphine combination in the treatment of opioid dependence. J. Psychopharmacol. 20, 806-814 (2006).
40. S. Wee, S. E. Specio, G. F. Koob, Effects of dose and session duration on cocaine selfadministration in rats. J. Pharmacol. Exp. Ther. 320, 1134 - 1143 (2007).
41. T. Eissenberg, M. K. Greenwald, R. E. Johnson, I. A. Liebson, G. E. Bigelow, M. L. Stitzer, Buprenorphine's physical dependence potential: Antagonist-precipitated withdrawal in humans. J. Pharmacol. Exp. Ther. 276, 449-459 (1996).
42. T. R. Kosten, J. H. Krystal, D. S. Charney, L. H. Price, C. H. Morgan, H. D. Kleber, Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend. 25, 73-78 (1990).
43. C. A. Paronis, J. Bergman, Buprenorphine and opioid antagonism, tolerance, and naltrexoneprecipitated withdrawal. J. Pharmacol. Exp. Ther. 336, 488-495 (2011).
44. E. M. Glover, M. Davis, Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: Tolerance, cross-tolerance, and blockade by naloxone. Psychopharmacology 198, 167-180 (2008).
45. S. H. Ahmed, P. J. Kenny, G. F. Koob, A. Markou, Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat. Neurosci. 5, 625- 626 (2002).
46. H. Aujla, R. Martin-Fardon, F. Weiss, Rats with extended access to cocaine exhibit increased stress reactivity and sensitivity to the anxiolytic-like effects of the mGluR 2/3 agonist LY379268 during abstinence. Neuropsychopharmacology 33, 1818-1826 (2008).
47. G. F. Koob, M. Le Moal, Addiction and the brain antireward system. Annu. Rev. Psychol. 59, 29-53 (2008).
48. S. D. Comer, S. T. Lac, C. L. Wyvell, M. E. Carroll, Combined effects of buprenorphine and a nondrug alternative reinforcer on i.v. cocaine self-administration in rats maintained under FR schedules. Psychopharmacology 125, 355 -360 (1996).
49. N. K. Mello, J. H. Mendelson, M. P. Bree, S. E. Lukas, Buprenorphine suppresses cocaine selfadministration by rhesus monkeys. Science 245, 859-862 (1989).
50. N. K. Mello, S. E. Lukas, J. H. Mendelson, J. Drieze, Naltrexone-buprenorphine interactions: Effects on cocaine self-administration. Neuropsychopharmacology 9, 211-224 (1993).
51. S. S. Negus, N. K. Mello, Effects of m-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: Role of μ-agonist efficacy. J. Pharmacol. Exp. Ther. 300, 1111 -1121 (2002).
52. N. F. Ramsey, J. M. van Ree, Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 40, 807-810 (1991).
53. W. A. Corrigall, K. M. Coen, Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology 104, 167-170 (1991).
54. A. Ettenberg, H. O. Pettit, F. E. Bloom, G. F. Koob, Heroin and cocaine intravenous selfadministration in rats: Mediation by separate neural systems. Psychopharmacology 78, 204-209 (1982).
55. S. E. Hemby, J. E. Smith, S. I. Dworkin, The effects of eticlopride and naltrexone on responding maintained by food, cocaine, heroin and cocaine/heroin combinations in rats. J. Pharmacol. Exp. Ther. 277, 1247-1258 (1996).
56. N. K. Mello, J. H. Mendelson, M. P. Bree, S. E. Lukas, Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 254, 926 -939 (1990).
57. S. D. Glick, K. E. Visker, I. M. Maisonneuve, Effects of cyclazocine on cocaine self-administration in rats. Eur. J. Pharmacol. 357, 9-14 (1998).
58. C. A. Bowen, S. S. Negus, R. Zong, J. L. Neumeyer, J. M. Bidlack, N. K. Mello, Effects of mixedaction κ/μ opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28, 1125-1139 (2003).
59. M. S. Todtenkopf, J. F. Marcus, P. S. Portoghese, W. A. Carlezon Jr., Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 172, 463 -470 (2004).
60. S. Wee, G. F. Koob, The role of the dynorphin -κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 210, 121-135 (2010).
61. B. Kögel, T. Christoph, W. Strassburger, E. Friderichs, Interaction of μ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur. J. Pain 9, 599-611 (2005).
62. E. A. Walker, M. M. Makhay, J. D. House, A. M. Young, In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J. Pharmacol. Exp. Ther. 271, 959-968 (1994).
63. V. F. Gellert, S. G. Holtzman, Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J. Pharmacol. Exp. Ther. 205, 536-546 (1978).
64. G. Schulteis, C. J. Heyser, G. F. Koob, Differential expression of response-disruptive and somatic indices of opiate withdrawal during the initiation and development of opiate dependence. Behav. Pharmacol. 10, 235-242 (1999).
65. J. W. Villiger, K. M. Taylor, Buprenorphine: Characteristics of binding sites in the rat central nervous system. Life Sci. 29, 2699-2708 (1981).